Conference Coverage

Transcatheter aortic valve-in-ring for mitral disease a winner

 

Key clinical point: Transcatheter mitral implantation of an aortic valve is a reasonable treatment strategy for high-surgical-risk patients with severe mitral valve disease.

Major finding: Thirty-day all-cause mortality following a transcatheter valve-in-ring procedure in unacceptably high surgical-risk patients with severe mitral valve disease due to a failing annuloplasty ring was 6.8%.

Study details: This prospective observational study included 60 patients who underwent transcatheter mitral valve replacement for severe mitral valve disease, half due to a failed annuloplasty ring and half secondary to mitral annular calcification.

Disclosures: The MITRAL trial was partially supported by Edwards Lifesciences. The study presenter reported receiving a research grant from the company.

Source: Guerrero M. No abstract.


 

REPORTING FROM TCT 2017

Survival climbing with operator experience

“In the early days of the TMVR MAC registry, the 30-day mortality rate was 37%. It came down to 22% in the middle third of the registry, then about 18% in the final third. Now we’ve got it down in MITRAL to 16.7%, but when you separate the rate in the transseptal versus the transatrial patients, it’s 13% versus 20%. The difference is not statistically significant, but it’s promising, and I think we are making great progress,” Dr. Guerrero said.

Safety and efficacy endpoints in MITRAL will be reported again at 1 year of follow-up.

The MITRAL trial was partially supported by Edwards Lifesciences. Dr. Guerrero reported receiving a research grant from that company and serving as a consultant to Tendyne Holdings/Abbott and on a speakers bureau for Abiomed.

SOURCE: Guerrero M. No abstract.

Next Article:

Carotid stenting isn’t safer than endarterectomy with contralateral carotid occlusion

Related Articles